ESMO 2023 | SunRISe-3: TAR-200 + CET or TAR-200 vs BCG in BCG-naive HR NMIBC

Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, discusses the main findings of the Phase II SunRISe-1 (NCT04640623) trial , evaluating the use of the intravesical drug delivery system TAR-200 with or without cetrelimab vs cetrelimab alone in patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.